A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
Nicolas Collongues, Guillaume Becker, Valérie Jolivel, Estelle Ayme‐Dietrich, de Sèze, Fabien Binamé, Christine Patte‐Mensah, Laurent Monassier, Ayikoe Guy Mensah‐Nyagan
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton's tyrosine kinase inhibitors, anti-apoptotic and antioxidant agents, sex hormones, statins, channel blockers, growth factors, and molecules preventing glutamate excitotoxicity have already been studied. Some of them have reached phase III clinical trials and carry a great message of hope for our patients with MS.